Download PDF
Int J Sports Med 2022; 43(13): 1084-1096
DOI: 10.1055/a-1797-7622
Review

Current Insights into Cellular Senescence and Myotoxicity Induced by Doxorubicin: The Role of Exercise and Growth Factors

Charalampos Andreou
1   Molecular Physiology Laboratory, Centre for Atherothrombosis & Metabolic Disease, Hull York Medical School, University of Hull
,
Antonios Matsakas
1   Molecular Physiology Laboratory, Centre for Atherothrombosis & Metabolic Disease, Hull York Medical School, University of Hull
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Doxorubicin is an anti-neoplasmic drug that prevents DNA replication but induces senescence and cellular toxicity. Intensive research has focused on strategies to alleviate the doxorubicin-induced skeletal myotoxicity. The aim of the present review is to critically discuss the relevant scientific evidence about the role of exercise and growth factor administration and offer novel insights about newly developed-tools to combat the adverse drug reactions of doxorubicin treatment on skeletal muscle. In the first part, we discuss current data and mechanistic details on the impact of doxorubicin on skeletal myotoxicity. We next review key aspects about the role of regular exercise and the impact of growth factors, administered either pharmacologically or via genetic interventions. Future strategies such as combination of exercise and growth factor administration remain to be established to combat the pharmacologically-induced myotoxicity.

Key words

myotoxicity - doxorubicin - exercise - skeletal muscle - growth factors


Publication History

Received: 12 December 2021

Accepted: 14 March 2022

Accepted Manuscript online:
14 March 2022

Article published online:
06 May 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 de Lima Junior EA, Yamashita AS, Pimentel GD. et al. Doxorubicin caused severe hyperglycaemia and insulin resistance, mediated by inhibition in AMPk signalling in skeletal muscle. J Cachexia Sarcopenia Muscle 2016; 7: 615-625
    CrossrefPubMedGoogle Scholar
  • 2 Gibson NM, Quinn CJ, Pfannenstiel KB. et al. Effects of age on multidrug resistance protein expression and doxorubicin accumulation in cardiac and skeletal muscle. Xenobiotica 2014; 44: 472-479
    CrossrefPubMedGoogle Scholar
  • 3 Gajadeera C, Willby MJ, Green KD. et al. Antimycobacterial activity of DNA intercalator inhibitors of Mycobacterium tuberculosis primase DnaG. J Antibiot (Tokyo) 2015; 68: 153-157
    CrossrefPubMedGoogle Scholar
  • 4 Slingerland M, Guchelaar HJ, Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today 2012; 17: 160-166
    CrossrefPubMedGoogle Scholar
  • 5 Yu AP, Pei XM, Sin TK. et al. Acylated and unacylated ghrelin inhibit doxorubicin-induced apoptosis in skeletal muscle. Acta Physiol (Oxf) 2014; 211: 201-213
    CrossrefPubMedGoogle Scholar
  • 6 Hiensch AE, Bolam KA, Mijwel S. et al. Doxorubicin-induced skeletal muscle atrophy: Elucidating the underlying molecular pathways. Acta Physiol (Oxf) 2020; 229: e13400
    CrossrefPubMedGoogle Scholar
  • 7 Rivankar S. An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther 2014; 10: 853-858
    CrossrefPubMedGoogle Scholar
  • 8 Baxter-Holland M, Dass CR. Doxorubicin, mesenchymal stem cell toxicity and antitumour activity: implications for clinical use. J Pharm Pharmacol 2018; 70: 320-327
    CrossrefPubMedGoogle Scholar
  • 9 Huang SC, Wu JF, Saovieng S. et al. Doxorubicin inhibits muscle inflammation after eccentric exercise. J Cachexia Sarcopenia Muscle 2017; 8: 277-284
    CrossrefPubMedGoogle Scholar
  • 10 Shrestha B, Pokhrel AR, Darsandhari S et al. Engineering streptomyces peucetius for doxorubicin and daunorubicin biosynthesis. In: Arora D, Sharma C, Jaglan S et al. (Eds.). Pharmaceuticals from Microbes: The Bioengineering Perspective. Springer Nature; 2019: 191–209
    PubMed
  • 11 Chen MB, Wu XY, Gu JH. et al. Activation of AMP-activated protein kinase contributes to doxorubicin-induced cell death and apoptosis in cultured myocardial H9c2 cells. Cell Biochem Biophys 2011; 60: 311-322
    CrossrefPubMedGoogle Scholar
  • 12 Spallarossa P, Altieri P, Barisione C. et al. p38 MAPK and JNK antagonistically control senescence and cytoplasmic p16INK4A expression in doxorubicin-treated endothelial progenitor cells. PLoS One 2010; 5: e15583
    CrossrefPubMedGoogle Scholar
  • 13 Sung JY, Lee KY, Kim JR. et al. Interaction between mTOR pathway inhibition and autophagy induction attenuates adriamycin-induced vascular smooth muscle cell senescence through decreased expressions of p53/p21/p16. Exp Gerontol 2018; 109: 51-58
    CrossrefPubMedGoogle Scholar
  • 14 Yoon KJ, Zhang D, Kim SJ. et al. Exercise-induced AMPK activation is involved in delay of skeletal muscle senescence. Biochem Biophys Res Commun 2019; 512: 604-610
    CrossrefPubMedGoogle Scholar
  • 15 Hulmi JJ, Nissinen TA, Rasanen M. et al. Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle. J Cachexia Sarcopenia Muscle 2018; 9: 417-432
    CrossrefPubMedGoogle Scholar
  • 16 Jiao J, Demontis F. Skeletal muscle autophagy and its role in sarcopenia and organismal aging. Curr Opin Pharmacol 2017; 34: 1-6
    CrossrefPubMedGoogle Scholar
  • 17 Yang J, Cao RY, Li Q. et al. Muscle Atrophy in Cancer. Adv Exp Med Biol 2018; 1088: 329-346
    CrossrefPubMedGoogle Scholar
  • 18 Nissinen TA, Degerman J, Rasanen M. et al. Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes. Sci Rep 2016; 6: 32695
    CrossrefPubMedGoogle Scholar
  • 19 Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009; 89: 381-410
    CrossrefPubMedGoogle Scholar
  • 20 Powers SK, Criswell D, Lawler J. et al. Influence of exercise and fiber type on antioxidant enzyme activity in rat skeletal muscle. Am J Physiol 1994; 266: R375-R380
    PubMedGoogle Scholar
  • 21 Powers SK, Lawler J, Criswell D. et al. Endurance-training-induced cellular adaptations in respiratory muscles. J Appl Physiol (1985) 1990; 68: 2114-2118
    CrossrefPubMedGoogle Scholar
  • 22 Camera DM, Smiles WJ, Hawley JA. Exercise-induced skeletal muscle signaling pathways and human athletic performance. Free Radic Biol Med 2016; 98: 131-143
    CrossrefPubMedGoogle Scholar
  • 23 Powers SK, Duarte JA, Le Nguyen B. et al. Endurance exercise protects skeletal muscle against both doxorubicin-induced and inactivity-induced muscle wasting. Pflugers Arch 2019; 471: 441-453
    CrossrefPubMedGoogle Scholar
  • 24 Powers SK, Bomkamp M, Ozdemir M. et al. Mechanisms of exercise-induced preconditioning in skeletal muscles. Redox Biol 2020; 35: 101462
    CrossrefPubMedGoogle Scholar
  • 25 Smuder AJ. Exercise stimulates beneficial adaptations to diminish doxorubicin-induced cellular toxicity. Am J Physiol Regul Integr Comp Physiol 2019; 317: R662-R672
    CrossrefPubMedGoogle Scholar
  • 26 Esaki M, Takemura G, Kosai K. et al. Treatment with an adenoviral vector encoding hepatocyte growth factor mitigates established cardiac dysfunction in doxorubicin-induced cardiomyopathy. Am J Physiol Heart Circ Physiol 2008; 294: H1048-H1057
    CrossrefPubMedGoogle Scholar
  • 27 Koleini N, Nickel BE, Wang J. et al. Fibroblast growth factor-2-mediated protection of cardiomyocytes from the toxic effects of doxorubicin requires the mTOR/Nrf-2/HO-1 pathway. Oncotarget 2017; 8: 87415-87430
    CrossrefPubMedGoogle Scholar
  • 28 Lawrence WT, Norton JA, Sporn MB. et al. The reversal of an Adriamycin induced healing impairment with chemoattractants and growth factors. Ann Surg 1986; 203: 142-147
    CrossrefPubMedGoogle Scholar
  • 29 Rasanen M, Degerman J, Nissinen TA. et al. VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection. Proc Natl Acad Sci U S A 2016; 113: 13144-13149
    CrossrefPubMedGoogle Scholar
  • 30 Harriss DJ, MacSween A, Atkinson G. Ethical Standards in Sport and Exercise Science Research: 2020 Update. Int J Sports Med 2019; 40: 813-817
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Bredahl EC, Hydock DS. Creatine Supplementation and Doxorubicin-Induced Skeletal Muscle Dysfunction: An Ex Vivo Investigation. Nutr Cancer 2017; 69: 607-615
    CrossrefPubMedGoogle Scholar
  • 32 Hydock DS, Lien CY, Jensen BT. et al. Characterization of the effect of in vivo doxorubicin treatment on skeletal muscle function in the rat. Anticancer Res 2011; 31: 2023-2028
    PubMedGoogle Scholar
  • 33 Gilliam LA, Moylan JS, Callahan LA. et al. Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy. Muscle Nerve 2011; 43: 94-102
    CrossrefPubMedGoogle Scholar
  • 34 Hayward R, Hydock D, Gibson N. et al. Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function. J Physiol Biochem 2013; 69: 177-187
    CrossrefPubMedGoogle Scholar
  • 35 D’Lugos AC, Fry CS, Ormsby JC. et al. Chronic doxorubicin administration impacts satellite cell and capillary abundance in a muscle-specific manner. Physiol Rep 2019; 7: e14052
    CrossrefPubMedGoogle Scholar
  • 36 Gilliam LA, Lark DS, Reese LR. et al. Targeted overexpression of mitochondrial catalase protects against cancer chemotherapy-induced skeletal muscle dysfunction. Am J Physiol Endocrinol Metab 2016; 311: E293-E301
    CrossrefPubMedGoogle Scholar
  • 37 Gouspillou G, Scheede-Bergdahl C, Spendiff S. et al. Anthracycline-containing chemotherapy causes long-term impairment of mitochondrial respiration and increased reactive oxygen species release in skeletal muscle. Sci Rep 2015; 5: 8717
    CrossrefPubMedGoogle Scholar
  • 38 Gilliam LAA, Fisher-Wellman KH, Lin CT. et al. The anticancer agent doxorubicin disrupts mitochondrial energy metabolism and redox balance in skeletal muscle. Free Radic Biol Med 2013; 65: 988-996
    CrossrefPubMedGoogle Scholar
  • 39 Tarpey MD, Amorese AJ, Balestrieri NP. et al. Doxorubicin causes lesions in the electron transport system of skeletal muscle mitochondria that are associated with a loss of contractile function. J Biol Chem 2019; 294: 19709-19722
    CrossrefPubMedGoogle Scholar
  • 40 Min K, Kwon OS, Smuder AJ. et al. Increased mitochondrial emission of reactive oxygen species and calpain activation are required for doxorubicin-induced cardiac and skeletal muscle myopathy. J Physiol 2015; 593: 2017-2036
    CrossrefPubMedGoogle Scholar
  • 41 Kavazis AN, Smuder AJ, Powers SK. Effects of short-term endurance exercise training on acute doxorubicin-induced FoxO transcription in cardiac and skeletal muscle. J Appl Physiol (1985) 2014; 117: 223-230
    CrossrefPubMedGoogle Scholar
  • 42 Smuder AJ, Kavazis AN, Min K. et al. Exercise protects against doxorubicin-induced markers of autophagy signaling in skeletal muscle. J Appl Physiol (1985) 2011; 111: 1190-1198
    CrossrefPubMedGoogle Scholar
  • 43 Smuder AJ, Kavazis AN, Hudson MB. et al. Oxidation enhances myofibrillar protein degradation via calpain and caspase-3. Free Radic Biol Med 2010; 49: 1152-1160
    CrossrefPubMedGoogle Scholar
  • 44 Smuder AJ, Kavazis AN, Min K. et al. Exercise protects against doxorubicin-induced oxidative stress and proteolysis in skeletal muscle. J Appl Physiol (1985) 2011; 110: 935-942
    CrossrefPubMedGoogle Scholar
  • 45 Sin TK, Tam BT, Yu AP. et al. Acute Treatment of Resveratrol Alleviates Doxorubicin-Induced Myotoxicity in Aged Skeletal Muscle Through SIRT1-Dependent Mechanisms. J Gerontol A Biol Sci Med Sci 2016; 71: 730-739
    CrossrefPubMedGoogle Scholar
  • 46 Yang MY, Lin PM, Liu YC. et al. Induction of cellular senescence by doxorubicin is associated with upregulated miR-375 and induction of autophagy in K562 cells. PLoS One 2012; 7: e37205
    CrossrefPubMedGoogle Scholar
  • 47 de Lima EA, de Sousa LGO, de STAA. et al. Aerobic exercise, but not metformin, prevents reduction of muscular performance by AMPk activation in mice on doxorubicin chemotherapy. J Cell Physiol 2018; 233: 9652-9662
    CrossrefPubMedGoogle Scholar
  • 48 Al-Khalaf HH, Colak D, Al-Saif M. et al. p16( INK4a) positively regulates cyclin D1 and E2F1 through negative control of AUF1. PLoS One 2011; 6: e21111
    CrossrefPubMedGoogle Scholar
  • 49 Idorn M, Thor Straten P. Exercise and cancer: from “healthy” to “therapeutic”?. Cancer Immunol Immunother 2017; 66: 667-671
    CrossrefPubMedGoogle Scholar
  • 50 Kim JS, Galvao DA, Newton RU. et al. Exercise-induced myokines and their effect on prostate cancer. Nat Rev Urol 2021; 18: 519-542
    CrossrefPubMedGoogle Scholar
  • 51 Pedersen L, Christensen JF, Hojman P. Effects of exercise on tumor physiology and metabolism. Cancer J 2015; 21: 111-116
    CrossrefPubMedGoogle Scholar
  • 52 Perez Regalado S, Leon J, Feriche B. Therapeutic approach for digestive system cancers and potential implications of exercise under hypoxia condition: what little is known? a narrative review. J Cancer Res Clin Oncol 2022; 148: 1107-1121
    CrossrefPubMedGoogle Scholar
  • 53 Ruiz-Casado A, Martin-Ruiz A, Perez LM. et al. Exercise and the hallmarks of cancer. Trends Cancer 2017; 3: 423-441
    CrossrefPubMedGoogle Scholar
  • 54 Bredahl EC, Busekrus RB, Hydock DS. The combined effect of creatine and resistance training on doxorubicin-induced muscle dysfunction. Nutr Cancer 2020; 72: 939-947
    CrossrefPubMedGoogle Scholar
  • 55 Quinn CJ, Hydock DS. Effects of endurance exercise and doxorubicin on skeletal muscle myogenic regulatory factor expression. Muscles Ligaments Tendons J 2017; 7: 418-425
    CrossrefPubMedGoogle Scholar
  • 56 Combs AB, Hudman SL, Bonner HW. Effect of exercise stress upon the acute toxicity of adriamycin in mice. Res Commun Chem Pathol Pharmacol 1979; 23: 395-398
    PubMedGoogle Scholar
  • 57 Bredahl EC, Pfannenstiel KB, Quinn CJ. et al. Effects of exercise on doxorubicin-induced skeletal muscle dysfunction. Med Sci Sports Exerc 2016; 48: 1468-1473
    CrossrefPubMedGoogle Scholar
  • 58 Dickinson JM, D’Lugos AC, Mahmood TN. et al. Exercise protects skeletal muscle during chronic doxorubicin administration. Med Sci Sports Exerc 2017; 49: 2394-2403
    CrossrefPubMedGoogle Scholar
  • 59 Kwon I. Protective effects of endurance exercise on skeletal muscle remodeling against doxorubicin-induced myotoxicity in mice. Phys Act Nutr 2020; 24: 11-21
    CrossrefPubMedGoogle Scholar
  • 60 Guigni BA, Fix DK, Bivona JJ. et al. Electrical stimulation prevents doxorubicin-induced atrophy and mitochondrial loss in cultured myotubes. Am J Physiol Cell Physiol 2019; 317: C1213-C1228
    CrossrefPubMedGoogle Scholar
  • 61 Yao CX, Shi JC, Ma CX. et al. EGF protects cells against dox-induced growth arrest through activating cyclin d1 expression. J Cell Biochem 2015; 116: 1755-1765
    CrossrefPubMedGoogle Scholar
  • 62 Koleini N, Nickel BE, Edel AL. et al. Non-mitogenic FGF2 protects cardiomyocytes from acute doxorubicin-induced toxicity independently of the protein kinase CK2/heme oxygenase-1 pathway. Cell Tissue Res 2018; 374: 607-617
    CrossrefPubMedGoogle Scholar
  • 63 Sontag DP, Wang J, Kardami E. et al. FGF-2 and FGF-16 protect isolated perfused mouse hearts from acute doxorubicin-induced contractile dysfunction. Cardiovasc Toxicol 2013; 13: 244-253
    CrossrefPubMedGoogle Scholar
  • 64 Wang S, Wang Y, Zhang Z. et al. Cardioprotective effects of fibroblast growth factor 21 against doxorubicin-induced toxicity via the SIRT1/LKB1/AMPK pathway. Cell Death Dis 2017; 8: e3018
    CrossrefPubMedGoogle Scholar
  • 65 Chen L, Xia W, Hou M. Mesenchymal stem cells attenuate doxorubicininduced cellular senescence through the VEGF/Notch/TGFbeta signaling pathway in H9c2 cardiomyocytes. Int J Mol Med 2018; 42: 674-684
    PubMedGoogle Scholar
  • 66 Chen T, Zhou G, Zhu Q. et al. Overexpression of vascular endothelial growth factor 165 (VEGF165) protects cardiomyocytes against doxorubicin-induced apoptosis. J Chemother 2010; 22: 402-406
    CrossrefPubMedGoogle Scholar
  • 67 Wang J, Xiang B, Dolinsky VW. et al. Cardiac fgf-16 expression supports cardiomyocyte survival and increases resistance to doxorubicin cytotoxicity. DNA Cell Biol 2018; 37: 866-877
    CrossrefPubMedGoogle Scholar
  • 68 Bailly K, Soulet F, Leroy D. et al. Uncoupling of cell proliferation and differentiation activities of basic fibroblast growth factor. FASEB J 2000; 14: 333-344
    CrossrefPubMedGoogle Scholar
  • 69 Jiang ZS, Srisakuldee W, Soulet F. et al. Non-angiogenic FGF-2 protects the ischemic heart from injury, in the presence or absence of reperfusion. Cardiovasc Res 2004; 62: 154-166
    CrossrefPubMedGoogle Scholar
  • 70 Scully D, Naseem KM, Matsakas A. Platelet biology in regenerative medicine of skeletal muscle. Acta Physiol (Oxf) 2018; 223: e13071
    CrossrefPubMedGoogle Scholar
  • 71 Stellos K, Kopf S, Paul A. et al. Platelets in regeneration. Semin Thromb Hemost 2010; 36: 175-184
    Article in Thieme ConnectPubMedGoogle Scholar
  • 72 Li H, Usas A, Poddar M. et al. Platelet-rich plasma promotes the proliferation of human muscle derived progenitor cells and maintains their stemness. PLoS One 2013; 8: e64923
    CrossrefPubMedGoogle Scholar
  • 73 Scully D, Sfyri P, Verpoorten S. et al. Platelet releasate promotes skeletal myogenesis by increasing muscle stem cell commitment to differentiation and accelerates muscle regeneration following acute injury. Acta Physiol (Oxf) 2019; 225: e13207
    CrossrefPubMedGoogle Scholar
  • 74 Scully D, Sfyri P, Wilkinson HN. et al. Optimising platelet secretomes to deliver robust tissue-specific regeneration. J Tissue Eng Regen Med 2020; 14: 82-98
    CrossrefPubMedGoogle Scholar
  • 75 Tsai WC, Yu TY, Chang GJ. et al. Platelet-rich plasma releasate promotes regeneration and decreases inflammation and apoptosis of injured skeletal muscle. Am J Sports Med 2018; 46: 1980-1986
    CrossrefPubMedGoogle Scholar
  • 76 Barlow J, Sfyri PP, Mitchell R. et al. Platelet releasate normalises the compromised muscle regeneration in a mouse model of hyperlipidaemia. Exp Physiol 2021; 106: 700-713
    CrossrefPubMedGoogle Scholar